Pharmacotherapy of hyperglycemia

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 15, 2009, Pages 2415-2432

  Kulasa, Kristen M ^a   Henry, Robert R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bile acid sequestrant; DPP 4; GLP 1 analog; GLP 1 receptor agonist; Hyperglycemia; Incretin; Pharmacotherapy; SGLT 2 inhibitor; Treatment; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ALOGLIPTIN; CHLORPROPAMIDE; COLESEVELAM; DAPAGLIFLOZIN; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOKINASE ACTIVATOR; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; TOLAZAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ABDOMINAL PAIN; ADD ON THERAPY; ANXIETY; ARTHRALGIA; BACKACHE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DIET; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DYSLIPIDEMIA; DYSPEPSIA; EDEMA; EXERCISE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; LEG PAIN; MONOTHERAPY; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PERIPHERAL EDEMA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SWEATING; THORAX PAIN; TREATMENT INDICATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS;

EID: 70349495861     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903196758     Document Type: Review

References (99)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-1053
2. Elrick H, Stimmler L, Hlad CJ, Jr., et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-1082 •• First study to show that an oral gluocse load elicits a stronger insulin response than an isoglycemic IV challenge; this led to the concept of the incretin effect.
3. Parthier C, Kleinschmidt M, Neumann P, et al. Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci USA 2007;104(35):13942-13947 (Pubitemid 350003317)
4. Orskov C, Rabenhoj L, Wettergren A, et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994;43(4):535-539 (Pubitemid 24096293)
5. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117(18):2340-2350 (Pubitemid 351653542)
6. Nikolaidis LA, Elahi D, Shen YT, et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289(6):H2401-8 (Pubitemid 41698549)
7. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146(1-3):243-249
8. Meier JJ, Nauck MA. Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 2008;4(11):606-607
9. Rachman J, Barrow BA, Levy JC, et al. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997;40(2):205-211 •• First study to show that administration of exogenous GLP-1 improves blood sugars. (Pubitemid 27060294)
10. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359(9309):824-830 (Pubitemid 34233752)
11. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-1100 •• First trials with the new GLP-1 receptor agonist exenatide. (Pubitemid 40616618)
12. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-2635 • First trials with the new GLP-1 receptor agonist exenatide. (Pubitemid 39441462)
13. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083-1091 • First trials with the new GLP-1 receptor agonist exenatide. (Pubitemid 40616617)
14. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146(7):477-485 (Pubitemid 351650556)
15. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143(8):559-569 (Pubitemid 41476552)
16. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50(2):259-267
17. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8(4):436-447 (Pubitemid 44349236)
18. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007;29(1):139-153
19. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type2 diabetes treated for at least 3years. Curr Med Res Opin 2008;24(1):275-286
20. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type2 diabetes mellitus. Diabetes Obes Metab 2006;8(4):419-428 (Pubitemid 44349234)
21. Frey CF, Zhou H, Harvey DJ, etal. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. Pancreas 2006;33(4):336-344
22. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32(5):834-838
23. Martinez J, ohnson CD, Sanchez-Paya J, et al. Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis. Pancreatology 2006;6(3):206-209
24. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25(4):1019-1027
25. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24weeks in antidiabetic drug-naive patients with type2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30(8):1448-1460
26. Nelson P, Poon T, Guan X, et al. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007;9(4):317-326 (Pubitemid 47340082)
27. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type2 diabetes. Diabetes Care 2007;30(6):1487-1493 (Pubitemid 46871159)
28. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372(9645):1240-50 • First study comparing short- and long-acting exenatide.
29. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43(9):1664-1669
30. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45(2):195-202 (Pubitemid 34208381)
31. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25(8):1398-1404 (Pubitemid 41071152)
32. Bjornsdottir I, Olsen A, Larsen U, et al. Metabolism and excretion of the once-daily human GLP-1 analog liraglutide in healthy subjects and its invitro degradation by dipeptidyl peptidase IV and neutral endopeptidase [abstract 891]. Diabetologia 2008;51(Suppl 1):S356
33. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662):473-481
34. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 2008;32(1):84-90
35. Buse JB. A study of two glucagon-like peptide-1 receptor agonists for the treatment of type2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomized, 26-week, open-label trial (LEAD-6). Lancet 2009;374(9683):39-47
36. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993;42(5):658-661 (Pubitemid 23127154)
37. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44(9):1126-1131
38. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29(12):2632-2637 (Pubitemid 44912190)
39. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29(12):2638-2643 (Pubitemid 44912191)
40. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type2 diabetes. Diabetes Care 2007;30(8):1979-87 • Initiation of combination sitagliptin and metformin showed impressive results.
41. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9(5):733-745 (Pubitemid 47261855)
42. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9(2):194-205 (Pubitemid 46206563)
43. Raz I, Chen Y, Wu M, etal. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24(2):537-550
44. Raz I, Hanefeld M, Xu L, etal. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type2 diabetes mellitus. Diabetologia 2006;49(11):2564-2571
45. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28(10):1556-1568 (Pubitemid 44841980)
46. Dejager S, Razac S, Foley JE, et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39(3):218-223 (Pubitemid 46580622)
47. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76(1):132-138 (Pubitemid 46240373)
48. Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38(6):423-428 (Pubitemid 44047965)
49. Ristic S, Byiers S, Foley J, etal. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7(6):692-698
50. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008;25(4):435-441
51. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30(2):217-223 (Pubitemid 46198322)
52. Bolli G, Dotta F, Rochotte E, etal. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10(1):82-90
53. Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1year in drug-naive patients with Type2 diabetes. Diabet Med 2007;24(9):955-961 (Pubitemid 47301637)
54. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type2 diabetes. Diabetes Obes Metab 2008;10(5):376-386
55. Rosenstock J, A-SA. Once-daily saxagliptin monotherapy improves glycemic control in drug-naive patients with type2 diabetes. Diabetes 2008;57(Suppl 1):517-P
56. Ravichandran S, Chacra AR. Saxagliptin added to a sulfonylurea is safe and more efficacious than uptitrating a sulfonylurea in patients with type2 diabetes [abstract 858]. Diabetologia 2008;51(Suppl 1):S342
57. Allen E, HP. Saxagliptin added to a thiazolidinedione improves glycaemic control in patients with inadequeately controlled type2 diabetes [abstract 859]. Diabetologia 2008;51(Suppl 1):S342
58. Fleck P, CR, Covington P, etal. Efficacy and safety of alogliptin monotherapy over 12weeks in patients with type2 diabetes. Diabetes 2008;57(Suppl 1):479-P
59. Mekki Q, FP, Wilson C, DeFronzo R. Efficacy and safety of alogliptin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise [abstract 862]. Diabetologia 2008;51(Suppl 1):S344
60. Ellis G, FP, Wilson C, etal. Alogliptin added to metformin therapy in patients with type2 diabetes reduces HbA1C without changing weight or increasing gastrointestinal symptoms or hypoglycemia [abstract 861]. Diabetologia 2008;51(Suppl 1):S343
61. Pratley R, KM, Fleck P, etal. Alogliptin added to sulfonylurea therapy in patients with type2 diabetes reduces HbA1C without increasing hypoglycemia. Diabetes 2008;57(Suppl 1):445-P
62. Pratley R, RJ, Fleck P, etal. Alogliptin added to pioglitazone therapy improves glycaemic control in patients with type 2 diabetes without increasing weight gain or hypoglycemia [abstract 860]. Diabetologia 2008;51(Suppl 1):S343
63. Rosenstock J, RM, Gross J, etal. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1C without increasing weight gain or hypoglycemia. Diabetes 2008;57(Suppl 1):444-P
64. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006;99(3):257-273
65. De Fabiani E, Mitro N, Gilardi F, et al. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 2003;278(40):39124-39132 (Pubitemid 37221815)
66. Suzuki T, Oba K, Futami S, etal. Blood glucose-lowering activity of colestimide in patients with type2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006;73(5):277-284 (Pubitemid 44663094)
67. Yamagata K, Daitoku H, Shimamoto Y, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 2004;279(22):23158-23165 (Pubitemid 38685621)
68. Bandisode MS, Boshell BR. Hypocholesterolemic activity of colestipol in diabetes. Curr Ther Res Clin Exp 1975;18(2):276-284
69. Duntsch G. Colestipol by hypercholesteremia in diabetics. Fortschr Med 1977;95(22):1492-1496
70. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121(6):416-422
71. Tonolo G, Melis MG, Formato M, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30(11):980-987
72. Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type2 diabetes mellitus with hypercholesterolemia. Endocr J 2007;54(1):53-58 (Pubitemid 46481671)
73. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type2 diabetes. Clin Ther 2007;29(1):74-83
74. Bays HE, Cohen DE. Cohen, Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type2 diabetes mellitus. Curr Med Res Opin 2007;23(7):1673-1684
75. Bays HE, Goldberg RB, Truitt KE, et al. Colesevelam hydrochloride therapy in patients with type2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008;168(18):1975-1983
76. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31(8):1479-1484
77. Welchol. prescribing information. Available from: http://www.welchol.com/ pdf/Welchol-PI.pdf.colesevelam HCl tablets [Last accessed 7 February 2009]
78. HV. Tubular reabsorption, in renal function. Little, Brown and Company: Boston; 1983. p. 65-68
79. Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2weeks in patients with type2 diabetes mellitus. Clin Pharmacol Ther 2009;85(5):513-519
80. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type2 diabetes. Diabetes Care 2009;32(4):650-7 • Promising new class of diabetes medication.
81. Basu A, etal. Type2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity. Diabetes 2001;50(6):1351-1362
82. Basu A, etal. Effects of type2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. Diabetes 2000;49(2):272-283
83. Basu R, etal. Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes. Diabetes 2004;53(8):2042-2050
84. Glyset. prescribing information. Available from: http://www.pfizer.com/ files/products/uspi-glyset.pdf.miglitol tablets [Last accessed 7 February 2009]
85. Precose. prescribing information. Available from: http://www.univgraph. com/Bayer/inserts/Precose.pdf.acarbose tablets [Last accessed 7 February 2009]
86. Glucophage. prescribing information. Available from: http://www. packageinserts.bms.com/pi/pi-glucophage-xr.pdf.metformin hydrochloride extended-release tablets [Last accessed 7 February 2009]
87. Januvia. prescribing information. Available from: http://www.merck.com/ product/usa/pi-circulars/j/januvia/ januvia-pi.pdf.sitagliptin tablets [Last accessed 7 February 2009]
88. Prandin. prescribing information. Available from: http://www.prandin.com/ docs/prandin-insert.pdf.repaglinide tablets [Last accessed 7 February 2009]
89. Starlix. prescribing information. Available from: http://www.pharma.us. novartis.com/product/pi/pdf/Starlix.pdf.nateglinide tablets [Last accessed 7 February 2009]
90. Amaryl. prescribing information. Available from: http://products.sanofi- aventis.us/amaryl/amaryl.pdf.glimepiride tablets [Last accessed 7 February 2009]
91. Glucotrol. prescribing information. Available from: http://www.pfizer. com/files/products/uspi-glucotrol-xl.pdf.glipizide [Last accessed 7 February 2009]
92. Micronase. prescribing information. Available from: http://www.pfizer. com/files/products/uspi-micronase.pdf.glyburide [Last accessed 7 February 2009]
93. Actos. prescribing information. Available from: http://www.actos.com/ actos/prescribinginfo.aspx.pioglitazone hydrochloride tablets [Last accessed 7 February 2009]
94. Avandia. prescribing information. Available from: http://us.gsk.com/ products/assets/us-avandia.pdf.rosiglitazone maleate tablets [Last accessed 7 February 2009]
95. Byetta. prescribing information. Available at: http://pi.lilly.com/us/ byetta-pi.pdf.exenatide [Last accessed 7 February 2009]
96. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24weeks in patients with type2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30(4):890-895 (Pubitemid 46556583)
97. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type2 diabetes. Diabetologia 2007;50(6):1148-1155 (Pubitemid 46701545)
98. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9(2):166-174 (Pubitemid 46206560)
99. Rosenstock J, Kim SW, Baron MA, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9(2):175-185 (Pubitemid 46206561)